Introduction
============

Cytokines are glycosylated proteins that allow communication among various cell types involved in immune response. Interleukins (ILs) are cytokines mainly produced by T-cells, as well by monocytes, macrophages and endothelial cells ([@b1-ijmm-35-01-0092],[@b2-ijmm-35-01-0092]). The different ILs share special biochemical or functional characteristics and are numbered in order of their identification. The emergence of new technologies is translating into a steady increase in the number of known molecules ([@b3-ijmm-35-01-0092]). In 2008, Lin *et al* ([@b4-ijmm-35-01-0092]) produced 3,400 recombinant secreted proteins that encode secreted proteins and extracellular domains of transmembrane proteins in 293T cells and examined their activities based on human monocyte screening assays. Subsequently, the authors ([@b4-ijmm-35-01-0092]) discovered a novel cytokine, IL-34. The human IL-34 protein is composed of 222 amino acids, has a molecular mass of 39 kDa and forms homodimers. It binds to the macrophage colony-stimulating factor (M-CSF) receptor, c-FMS (also known as CSF-1 receptor), expressed on the cell surface of human monocytes and has a stronger, although short-lived effect compared to M-CSF. IL-34 has been shown to be involved in the process of osteoclastogenesis and rheumatoid arthritis (RA) ([@b5-ijmm-35-01-0092]--[@b8-ijmm-35-01-0092]). IL-34 has been shown to promote the proliferation, survival and differentiation of monocytes and macrophages, the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and inflammatory processes. It also plays an important role in the regulation of osteoclast proliferation and differentiation, and in the regulation of bone resorption ([@b5-ijmm-35-01-0092]--[@b8-ijmm-35-01-0092]).

IL-34 and M-CSF both signal via the same receptor, the M-CSF receptor. Although IL-34 and M-CSF show no appreciable similarity in their primary structure, they are evolutionally distant ligands, but are structurally related ([@b9-ijmm-35-01-0092]). There is evidence indicating that the M-CSF-IL-34-c-FMS axis is involved in the initiation, growth and metastasis of tumors ([@b10-ijmm-35-01-0092],[@b11-ijmm-35-01-0092]). M-CSF levels may constitute a useful biomarker for a number of types of cancer, as it is expressed at high levels in a number of types of cancer, including breast cancer, ovarian cancer and colorectal carcinoma and its expression correlates with a poor prognosis ([@b12-ijmm-35-01-0092]). The direct inhibition of M-CSF or the inhibition of c-FMS kinase activity can lead to significant changes in the growth of grafted tumors (13.14). Tumor-associated macrophages are the most abundant component of the leukocyte infiltrate of solid tumors. In M-CSF-deficient mice (M-CSF^op/op^ or M-CSF^−/−^), the growth of the primary tumor and the metastatic spread of tumor cells has been shown to be significantly reduced due to the inability of angiogenesis to feed the tumors ([@b12-ijmm-35-01-0092]--[@b15-ijmm-35-01-0092]).

However, studies on the role of IL-34 in tumorigenesis. In the present study, we identified the IL-34 gene in various mammalian genomes by comparative genomic analyses. The conserved transcription factor-binding sites within the promoter region of the human IL-34 gene were then searched. Analyses of the expression data, functional relevant single nucleotide polymorphisms (SNPs) and comparative proteomic analysis were also conducted. Furthermore, a meta-analysis of the prognostic value of the IL-34 gene in various types of cancer was performed.

Materials and methods
=====================

Identification of the novel IL-34 gene in vertebrate genomes and integrative genomic analyses
---------------------------------------------------------------------------------------------

All the IL-34 gene and amino acid sequences were obtained from the Ensembl database (<http://www.ensembl.org/index.html>), based on orthologous and paralogous relationships. The gained IL-34 sequences were applied as queries to search the IL-34 gene using BLAST at the National Center for Biotechnology Information (NCBI), in order to confirm whether their best hit was an IL-34 gene ([@b16-ijmm-35-01-0092]--[@b18-ijmm-35-01-0092]). The number and length of IL-34 exons and introns in all competent sequences were investigated for exon-intron conservation analyses. The number, length and structures of the exons and introns in IL-34 in all species were also collected from the Ensembl database (<http://www.ensembl.org/index.html>). Conserved transcription factor-binding sites within the promoter region of the human IL-34 gene were obtained from SABiosciences' proprietary database which combines Text Mining Application and data from the UCSC Genome Browser ([@b19-ijmm-35-01-0092]--[@b21-ijmm-35-01-0092]).

Comparative proteomic analysis of IL-34 protein
-----------------------------------------------

The protein coding sequences of IL-34 were aligned using ClustalW software implemented in MEGA 5.05. We constructed a maximum likelihood (ML) tree of IL-34 amino acid sequences using MEGA 5.05 with the optimal model (Kimura 2-parameter model). For the relative support of the internal node, bootstrap analysis was performed with 1,000 replications for ML reconstructions ([@b22-ijmm-35-01-0092]). The program CodeML implemented in the PAML 4.7 software package was used to investigate whether the IL-34 protein is under positive selection ([@b23-ijmm-35-01-0092]). The site-specific model was exerted using likelihood ratio tests (LRTs) to compare the M7 (null model) with the M8 model. M7 is a null model that does not allow for any codons with ω \>1, whereas the M8 model allows for positively selective sites (ω \>1). When the M8 model was fitted to the data more efficiently (P-value \<0.05) than the null model (M7), the presence of sites with ω \>1 was suggested. On the contrary, the results of P-value \>0.05 proved the absence of sites with ω \>1. Twice the log likelihood difference between the two compared models (2Δl) was compared against χ^2^ with critical values of 5.99 and 9.21 at 0.05 and 0.01 significance levels, respectively, as previously described ([@b24-ijmm-35-01-0092]).

Functionally relevant SNP evaluation of the human IL-34 gene and identification of somatic mutations in human cancer
--------------------------------------------------------------------------------------------------------------------

Functionally relevant SNPs of the human IL-34 gene were identified as previously described ([@b16-ijmm-35-01-0092]--[@b21-ijmm-35-01-0092]). The SNPs were extracted from the Ensembl (<http://www.ensembl.org>) and the NCBI SNPdb (<http://www.ncbi.nlm.nih.gov>) databases. The SNPs that disrupted exonic splicing enhancer/exonic splicing silencer (ESE/ESS) motifs and cause missence mutations were also identified. The identification of somatic mutations of the human IL-34 gene in human cancer was conducted in the Catalogue of Somatic Mutations in Cancer (COSMIC), a database for mining complete cancer genomes in the catalogue of somatic mutations in cancer ([@b25-ijmm-35-01-0092]).

In silico expression analyses of the human IL-34 gene
-----------------------------------------------------

Expressed sequence tags (ESTs) derived from the human IL-34 gene were searched for using the BLAST programs as previously described ([@b26-ijmm-35-01-0092]--[@b29-ijmm-35-01-0092]). The human IL-34 gene (NM_152456) was used as query sequences for the BLAST programs. The expression profiles for normal human tissues were obtained from GeneAnnot ([@b30-ijmm-35-01-0092]) and ArrayExpress ([@b31-ijmm-35-01-0092]) databases. Northern analysis of the NCBI uniGene dataset was also performed ([@b19-ijmm-35-01-0092]--[@b21-ijmm-35-01-0092]).

Meta-analysis of the prognostic value of the IL-34 gene in cancer
-----------------------------------------------------------------

A database termed 'PrognoScan' has been previously developed ([@b32-ijmm-35-01-0092]). This database includes a large collection of publicly available cancer microarray datasets with clinical annotation, as well as a tool for assessing the biological association between gene expression and prognosis. PrognoScan employs the minimum P-value approach for grouping patients for survival analysis. PrognoScan provides a powerful platform for evaluating potential tumor markers and therapeutic targets and is publicly accessible at <http://www.sabiosciences.com>. The human IL-34 gene was used as an input source as a query and the data were collected for analysis.

Results
=======

Comparative proteomic analysis of IL-34 protein identified in vertebrate genomes
--------------------------------------------------------------------------------

All the IL-34 gene and protein sequences were collected from the Ensembl database and confirmed by BLAST at NCBI. The complete IL-34 gene was identified in the human, chimpanzee, gibbon, macaque, orangutan, marmoset, bushbaby, pika, squirrel, rat, mouse, kangaroo rat, elephant, cat, dog, panda, ferret, pig, horse, cow, flycatcher, chicken, zebrafish, platyfish and tilapia. The sequence and structural alignment of IL-34 is illustrated in [Fig. 1](#f1-ijmm-35-01-0092){ref-type="fig"}. The phylogenetic tree was constructed according to the protein coding sequences of IL-34 using the ML method ([Fig. 2](#f2-ijmm-35-01-0092){ref-type="fig"}). The IL-34 gene from the primate lineage, rodent lineage and teleost lineage forms a species-specific cluster. The exon-intron information collected from the Ensembl database is presented in [Table I](#tI-ijmm-35-01-0092){ref-type="table"} and [Fig. 3](#f3-ijmm-35-01-0092){ref-type="fig"}. In the majority of genomes, the IL-34 gene has 6 exons with similar lengths in different species ([Table I](#tI-ijmm-35-01-0092){ref-type="table"}). In the majority of vertebrates, the IL-34 gene shows exon-intron conservation with 5 introns and similar sizes of each intron. With exception, there are 8 exons and 7 introns in the IL-34 gene in the kangaroo rat. Moreover, the IL-34 gene in the platyfish and tilapia contains 7 exons and 6 introns. Thus, the intron deletions of the IL-34 gene may occur during the evolutionary process in fish. Furthermore, site-specific tests for positive selection were performed for vertebrate, mammalian, primate and mammalian excluding primate, rodent and teleost lineages. Although some positive selection sites were computed, only the 2Δl of M7 and M8 of mammalian IL-34 was \>5.99, indicating that the M8 model was more efficient than the M7 model in fitting the data. It seemed that mammalian IL-34 was under positive selecetion pressure with the identified positively selected site, 196Val ([Table II](#tII-ijmm-35-01-0092){ref-type="table"}).

Expression profile of the human IL-34 gene
------------------------------------------

By EST sequence searching, the human IL-34 gene was found to be expressed in the adult and fetal brain, the hippocampus, spleen, embryonic stem cells, heart, medulla, lung, testes, ovaries, metastatic chondrosarcoma, epidermis, keratinocytes, osteoarthritic cartilage, adipose tissue, choroid, eyes, amygdala, kidneys, thymus, small intestine, hypothalamus, islets of Langerhans, glioblastoma and the retinal pigment epithelium. The investigation of available microarray analyses and 'virtual northern blot analysis' revealed a predominant expression of IL-34 in the lymph nodes, brain, heart, skeletal muscle, colon, adipocyte, kidneys, liver, lungs, thyroid, adrenal gland, ovaries, prostate and testes. When performing a search in the PrognoScan database, the human IL-34 gene was also found to be expressed in various types of cancer, such as blood, brain, breast, colorectal, eye, head and neck, lung, ovarian and skin cancer.

Comparative genomic anlaysis of the human IL-34 gene
----------------------------------------------------

The upstream transcription factor 1 (USF1), regulatory factor X-1 (RFX1), the Sp1 transcription factor 1, POU class 3 homeobox 2 (POU3F2) and the forkhead box L1 (FOXL1) regulatory transcription factor binding sites were identified in the IL-34 gene upstream (promoter) region.

Functionally relevant SNP evaluation of the human IL-34 gene and identification of somatic mutations in human cancer
--------------------------------------------------------------------------------------------------------------------

A total of 2,141 available SNPs were identified in the human IL-34 gene. Among these SNPs, a total of 55 SNPs were functionally relevant; these included 32 SNPs causing missense mutations, 3 exonic splicing enhancer SNPs and 20 SNPs causing nonsense mutations ([Table III](#tIII-ijmm-35-01-0092){ref-type="table"}). As presented in [Table IV](#tIV-ijmm-35-01-0092){ref-type="table"}, by performing a search of the COSMIC database, we identified 18 somatic mutations of the IL-34 gene in cancer.

Meta-analysis of the prognostic value of the human IL-34 gene in cancer
-----------------------------------------------------------------------

When the name of a gene is submitted, PrognoScan displays a summary in table format of tests for the gene with columns for dataset, cancer type, subtype, endpoint, cohort, contributor, array type, probe ID, number of patients, optimal cutpoint, Pmin and Pcor. Among the databases which detected the expression of the IL-34 gene, 5 out of 40 tests revealed an association between the expression of the IL-34 gene and cancer prognosis (blood cancer, 1/4; brain cancer, 1/4; breast cancer, 0/11; colorectal cancer, 1/7; eye cancer, 0/1; head and neck cancer, 0/3; lung cancer, 2/6; ovarian cancer, 0/3; and skin cancer, 0/1) with a 5% significance level ([Table V](#tV-ijmm-35-01-0092){ref-type="table"}). Among the two types of lung cancer, the lower expression of the IL-34 gene was related to poor survival and was found in non-small cell lung cancer (NSCLC) case (GSE8894). However, a higher expression of the IL-34 gene was related to poor survival in a case of adenocarcinoma (GSE31210). As for blood cancer cases and colorectal cancer, we found that a lower expression of the IL-34 gene was associated with poor survival. However, in the brain cancer cases, a higher expression of the IL-34 gene was related to poor survival.

Discussion
==========

IL-34 was identified by functional screening of a library of secreted proteins, based on its ability to support human monocyte survival and to promote, with the same efficiency as M-CSF, the formation of the colony forming unit-macrophage (CFU-M) in human bone marrow cell cultures ([@b4-ijmm-35-01-0092]).

In the present study, we identified the complete IL-34 gene in 25 various mammalian genomes, including the human, chimpanzee, gibbon, macaque, orangutan, marmoset, bushbaby, pika, squirrel, rat, mouse, kangaroo rat, elephant, cat, dog, panda, ferret, pig, horse, cow, flycatcher, chicken, zebrafish, platyfish and tilapia genomes. In addition, we found that IL-34 existed in all types of vertebrates, including fish, amphibians, birds and mammals. The IL-34 gene has a similar 7 exon/6 intron gene organization in various species, and genes in the IL-34 loci were syntenically conserved ([@b33-ijmm-35-01-0092],[@b34-ijmm-35-01-0092]). The phylogenetic tree demonstrated that the IL-34 gene from the primate lineage, rodent lineage and teleost lineage formed a species-specific cluster. From the alignment and phylogenetic tree, mammalian IL-34 was conversed among vertebrate genomes, suggesting that the function of the IL-34 gene plays an important physiological role in all vertebrates in the long evolutionary process. It seemed that the mammalian IL-34 gene was under positive selection pressure with the identified positively selected site, 196Val. This is in accordance the with multiple biological functions of a cytokine, which plays a key role in the immune system.

IL-34 mRNA is widely expressed in various types of tissue, including tissue of the heart, brain, lung, liver, kidneys, thymus and spleen ([@b4-ijmm-35-01-0092]). Accordingly, by EST sequence searching, the IL-34 gene was also found to be expressed in various other types of tissues and cells, including the hippocampus, embryonic stem cells, medulla, testes, ovaries, metastatic chondrosarcoma, epidermis, keratinocytes, osteoarthritic cartilage, adipose tissue, choroid, eyes, amygdala thymus, small intestine, hypothalamus, islets of Langerhans, glioblastoma and the retinal pigment epithelium. This suggests that the IL-34 gene is widely expressed in many types of tissues and organs. The investigation of available microarray analyses and 'virtual northern blot analysis' confirmed the predominant expression of IL-34 in the lymph nodes, brain, heart, skeletal muscle, colon, adipocyte, kidneys, liver, lung, thyroid, adrenal gland, ovaries, prostate and testes. A total of 55 functionally relevant SNPs, including 32 SNPs causing missense mutations, 3 exonic splicing enhancer SNPs and 20 SNPs causing nonsense mutations were identified from 2,141 available SNPs in the human IL-34 gene, which may affect the multiple functions of IL-34. However, the effects of these SNPs on the physiological and pathological function of IL-34 require further investigation.

IL-34 and M-CSF both signal via the same receptor, the M-CSF receptor, c-FMS. It has been shown that M-CSF is expressed at high levels in many types of tumor, including breast cancer, ovarian cancer and colorectal carcinoma and correlates with a poor prognosis ([@b10-ijmm-35-01-0092]--[@b15-ijmm-35-01-0092]). However, studies on the role of IL-34 in tumor development are limited. In the present study, we firstly found that IL-34 was indeed expressed in various types of cancer, such as blood, brain, breast, colorectal, eye, head and neck, lung, ovarian and skin cancer. A total of 5 out of 40 tests (1 blood cancer, 1 brain cancer, 1 colorectal cancer and 2 lung cancer) revealed an association between IL-34 gene expression and cancer prognosis. The mechanisms responsible for the involvement of IL-34 in the progression of these tumors require further investigation. It should be noted that the association between the expression of IL-34 and prognosis varies in different types of cancer, even in the same type of cancer from different databases. This suggests that the function of IL-34 in these tumors may be multidimensional, not only functioning as a tumor inhibitor or promoter. Moreover, we identified 18 somatic mutations of IL-34 in cancer tissue in the present study. The mechanisms through which these mutations affect tumor formation require further investigation. These data suggest that IL-34, similar to M-CSF, is involved in tumor formation.

USF1, RFX1, Sp1, POU3F2 and FOXL1 regulatory transcription factor binding sites were identified in the IL-34 gene upstream (promoter) region. USF-1 is an important transcription factor that participates in glucose metabolism and tumorigenesis. It has a negative effect on cell proliferation in some cell types and stabilizes the p53 protein and promotes a transient cell cycle arrest, in the presence of DNA damage ([@b34-ijmm-35-01-0092],[@b35-ijmm-35-01-0092]). RFX1 is unique transcription factor that contains a highly conserved 76-amino-acid DNA binding domain. RFX1 can directly regulate CD44 expression ([@b36-ijmm-35-01-0092],[@b37-ijmm-35-01-0092]). This mechanism may contribute to the effects of RFX1 on the proliferation, survival and invasion of glioblastoma cells. Sp1 is a member of the Sp/Krüppel-like factor (KLF) family of transcription factors that play a critical role in embryonic and early postnatal development, differentiation, cell cycle regulation and in multiple diseases, including cancer ([@b38-ijmm-35-01-0092]--[@b41-ijmm-35-01-0092]). POU domain transcription factors are present in a number of cell lineages where they perform various functions, either as ubiquitous regulators of 'housekeeping' genes, or as developmental- and lineage-specific coordinators of cell fate decisions ([@b42-ijmm-35-01-0092]). POU3F2 has been shown to be responsive to MAPK pathway activation and to modulate the levels of microphthalmia-associated transcription factor (MITF) so as to suppress the differentiated melanocytic phenotype and to enhance tumor metastasis ([@b29-ijmm-35-01-0092]). FOXL1 is located at the junction of multiple signaling pathways and plays critical roles in a variety of physiological and pathological processes, including cancer development. These tumor-related transcriptional factors may be involved in the effects of IL-34 in tumors ([@b28-ijmm-35-01-0092],[@b43-ijmm-35-01-0092],[@b44-ijmm-35-01-0092]).
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![Sequence and structural alignment of vertebrate interleukin-34 (IL-34). All the IL-34 gene and protein sequences were collected from the Ensembl database and confirmed by BLAST at the National Center for Biotechnology Information (NCBI). The complete IL-34 gene was identified in 25 various mammalian genomes, such as the human, chimpanzee, gibbon, macaque, orangutan, marmoset, bushbaby, pika, squirrel, rat, mouse, kangaroo rat, elephant, cat, dog, panda, ferret, pig, horse, cow, flycatcher, chicken, zebrafish, platyfish and tilapia genomes.](IJMM-35-01-0092-g00){#f1-ijmm-35-01-0092}

![The phylogenetic tree was constructed according to the protein coding sequences of interleukin-34 (IL-34) using the maximum likelihood method. The IL-34 gene from the primate lineage, rodent lineage and teleost lineage formed a species-specific cluster.](IJMM-35-01-0092-g01){#f2-ijmm-35-01-0092}

![Exon-intron conservation of the interleukin-34 (IL-34) gene among different species. In the majority of vertebrates, the IL-34 gene showed an exon-intron conservation with 5 introns and similar sizes of each intron. With exception, there are 8 exons and 7 introns in the IL-34 gene in the kangaroo rat. Moreover, in platyfish and tilapia, the IL-34 gene contains 7 exons and 6 introns.](IJMM-35-01-0092-g02){#f3-ijmm-35-01-0092}

###### 

Exon and intron lengths of IL-34.

                 Length (bp)                                                                                                
  -------------- ------------- -------- ----- ------- ---- ------- ----- ------- ----- ------- ----- ------- ---- ---- ---- -----
  Human          28            7,562    134   1,930   78   280     162   2,496   136   243     191   \-      \-   \-   \-   729
  Chimpanzee     28            8,179    134   1,926   78   280     162   2,495   136   250     191   \-      \-   \-   \-   729
  Gibbon         28            6,472    134   1,930   78   280     162   2,538   136   250     191   \-      \-   \-   \-   729
  Orangutan      28            7,643    134   2,042   78   280     162   2,563   136   258     191   \-      \-   \-   \-   729
  Macaque        28            7,369    134   2,064   78   288     162   2,531   136   239     191   \-      \-   \-   \-   729
  Marmoset       28            7,789    142   4,152   27   117     205   2,848   136   236     191   \-      \-   \-   \-   729
  Bushbaby       15            487      147   1,461   78   239     162   1,589   136   236     170   \-      \-   \-   \-   711
  Cat            28            6,405    134   787     78   285     162   2,902   136   230     173   \-      \-   \-   \-   711
  Dog            28            6,254    134   940     78   281     162   2,366   136   238     173   \-      \-   \-   \-   711
  Panda          28            5,018    134   797     78   284     162   2,066   136   230     173   \-      \-   \-   \-   711
  Horse          28            5,227    134   841     78   284     162   2,162   136   217     176   \-      \-   \-   \-   714
  Ferret         28            4,504    134   771     78   306     162   2,043   136   234     173   \-      \-   \-   \-   711
  Cow            28            5,849    134   751     78   261     162   2,879   133   229     170   \-      \-   \-   \-   705
  Rat            28            5,484    134   1,125   78   269     159   5,154   136   264     170   \-      \-   \-   \-   705
  Mouse          28            5,672    134   684     78   258     162   5,463   136   195     170   \-      \-   \-   \-   708
  Squirrel       28            5,565    134   789     78   277     162   3,231   136   210     185   \-      \-   \-   \-   723
  Kangaroo rat   28            3,351    134   1,060   78   223     162   1,055   136   202     160   4       16   2    15   729
  Flycatcher     28            92       104   293     78   84      174   3,627   139   99      20    \-      \-   \-   \-   543
  Chicken        28            86       104   623     78   108     174   1,225   133   82      20    \-      \-   \-   \-   537
  Zebrafish      40            4,445    107   431     81   3,052   201   142     169   3,375   44    \-      \-   \-   \-   642
  Platyfish      40            26,738   104   1,344   78   256     78    4,479   108   2,376   184   4,042   86   \-   \-   678
  Tilapia        37            11,964   104   461     78   154     78    2,170   108   4,072   184   799     59   \-   \-   648

IL-34, interleukin-34.

###### 

Site-specific tests for positive selection on IL-34.

  Species                       Models                                                     Estimates of parameters   lnL            2Δl        Positively selected sites
  ----------------------------- ---------------------------------------------------------- ------------------------- -------------- ---------- ------------------------------------------------------
  Vertebrate                    M7                                                         P=1.03903, Q=5.39585      −4659.912970   2.057682   NS
  M8                            P0=0.98039, P=1.20110, Q=7.10944 (P1=0.01961) w=1.00000    −4657.855288                                        
  Mammalian                     M7                                                         P=0.48941, Q=1.45186      −4490.139825   6.824409   196 V[a](#tfn2-ijmm-35-01-0092){ref-type="table-fn"}
  M8                            P0=0.96625, P=0.63368, Q=2.34086 (P1=0.03375), w=1.81330   −4483.315416                                        
  Primate                       M7                                                         P=0.01895, Q=0.02238      −1715.925824   0.033788   NS
  M8                            P0=0.56073, P=0.00997, Q=0.16501 (P1=0.43927) w=1.00000    −1715.959612                                        
  Mammalian excluding primate   M7                                                         P=0.30844, Q=1.06769      −3530.180011   2.160234   200 Q[a](#tfn2-ijmm-35-01-0092){ref-type="table-fn"}
  M8                            P0=0.98088, P=0.35332, Q=1.40393 (P1=0.01912) w=2.08098    −3528.019777                                        
  Rodent                        M7                                                         P=0.33256, Q=1.26857      −1743.972997   0.000104   NS
  M8                            P0=0.99999, P=0.33225, Q=1.26708 (P1=0.00001) w=3.17132    −1743.973101                                        
  Teleost                       M7                                                         P=0.55893, Q=1.64564      −1656.009963   0.088367   NS
  M8                            P0=0.99243, P=0.58684, Q=1.81573 (P1=0.00757) w=8.77551    −1655.921596                                        

The positively selected sites were identified with posterior probability ≥0.95 using the Bayes empirical Bayes (BEB) approach.

lnL, the log-likelihood difference between the two models; 2Δl, twice the log-likelihood difference between the two models (in all species, 2Δl \<9.21, the P-value is more than the significance level 0.05, indicating that the M8 model was more efficient than the M7 model); NA, not allowed; NS, not shown (sites under positive selection did not reach the significance level of 0.95). IL-34, interleukin-34.

###### 

Functionally relevant SNP evaluation of the human IL-34 gene.

  SNP ID         Chr 16 position sequence   Sequence        Type   Amino acid change
  -------------- -------------------------- --------------- ------ -------------------
  rs200158701    70680854(+)                CCATGC/TCCCGG   mis    PS
  rs192337001    70680866(+)                GCTTCA/CCCTGG   mis    TP
  rs139133476    70688459(+)                CCTTGG/CCGTGG   mis    AG
  rs142890682    70688461(+)                TTGGCG/ATGGCC   mis    MV
  rs118062333    70690511(+)                AACACT/CACTTC   mis    HY
  rs200597979    70690960(+)                GGGCCA/GCCCAT   mis    HR
  rs8046424      70690989(+)                AGGTGC/GAGACG   mis    QE
  rs187166563    70693576(+)                CCCAGA/GGCCAA   mis    EG
  rs142214904    70693626(+)                GCTTCC/TGGGTC   mis    RW
  rs7206509      70693945(+)                GCCAAG/CTCCTC   mis    TS
  rs201277640    70693984(+)                GTATGC/TGGCCA   mis    AV
  rs202122982    70694001(+)                TGTACC/TCTCCG   mis    PS
  rs148286339    70694011(+)                GCCCCC/TGTGGT   mis    PL
  rs141513638    70694056(+)                GAGGCC/TGGTCA   mis    PL
  rs112639369    70694073(+)                AGGGCG/AAGGGC   mis    KE
  rs1444643201   70694076(+)                GCGAGG/AGCCTC   mis    SG
  rs367851338    70693627(+)                CTTCCA/GGGTCA   mis    QR
  rs368143418    70690933(+)                TGAGTC/TGGTGC   mis    SL
  rs374665339    70690963(+)                CCACCC/TATCCT   mis    PL
  rs368923655    70691023(+)                CCTCAC/TGGTGA   mis    TM
  rs368367274    70693597(+)                GGTGCA/GGCCCA   mis    QR
  rs200891924    70693560(+)                TGTCCC/ATCTTG   mis    IL
  rs372998917    70694041(+)                CTCCAC/TGGGCT   mis    TM
  rs370436386    70690927(+)                TGCCAC/TTGAGT   mis    TL
  rs144427482    70690571(+)                CCAACG/ATCACC   mis    IV
  rs201108464    70693569(+)                TGAATG/ACCCCA   mis    TA
  rs144144426    70690541(+)                GTGTGC/TCTTAC   mis    PS
  rs377411431    70690885(+)                CGAGCG/TGGAGC   mis    RL
  rs369011177    70680875(+)                GGCTGC/TGCTGT   mis    RC
  rs145782768    70693979(+)                TTGCAG/CTATGC   mis    HQ
  rs201784459    70694005(+)                CCCTCC/TGCCCC   mis    PL
  rs200488835    70693655(+)                TCCTGC/GTGTAA   mis    CW
  rs3813904      70680744(+)                TGACTG/CAGTGA   ese    
  rs3813905      70680850(+)                ACCACC/GATGCC   ese    
  rs4985556      70694000(+)                CTGTAC/ACCTCC   ese    

A total of 55 SNPs were functionally relevant; including 32 SNPs causing missense mutations, 3 exonic splicing enhancer SNPs and 20 SNPs causing nonsense mutations. SNP, single nucleotide polymorphism; IL-34, interleukin-34; mis, missense; ese, exonic splicing enhancer.

###### 

Somatic mutations of IL-34 in cancer tissue.

  Position (AA)   Mutation (CDS)    Mutation (amino acid)   Mutation ID (COSM)   Count   Mutation type
  --------------- ----------------- ----------------------- -------------------- ------- ------------------------------
  4               c.11G\>A          p.G4D                   COSM973055           1       Substitution - missense
  9               c.25C\>T          p.R9C                   COSM3691133          1       Substitution - missense
  33              c.99G\>A          p.E33E                  COSM704311           1       Substitution - coding silent
  38              c.114G\>A         p.T38T                  COSM973057           1       Substitution - coding silent
  42              c.125_126GG\>AA   p.R42Q                  COSM143555           1       Substitution - missense
  59              c.176C\>T         p.P59L                  COSM108032           1       Substitution - missense
  61              c.182A\>G         p.N61S                  COSM3387573          1       Substitution - missense
  104             c.311C\>T         p.S104L                 COSM435667           1       Substitution - missense
  155             c.465C\>T         p.N155N                 COSM328594           9       Substitution - coding silent
  170             c.508C\>T         p.R170W                 COSM194870           1       Substitution - missense
  183             c.549C\>A         p.S183R                 COSM3402448          1       Substitution - missense
  197             c.589C\>T         p.Q197\*                COSM1379321          1       Substitution - nonsense
  197             c.590A\>G         p.Q197R                 COSM1379322          1       Substitution - missense
  197             c.591G\>A         p.Q197Q                 COSM40324            1       Substitution - coding silent
  208             c.623C\>T         p.A208V                 COSM417292           2       Substitution - missense
  208             c.624G\>A         p.A208A                 COSM1177412          1       Substitution - coding silent
  217             c.651G\>A         p.P217P                 COSM1379323          1       Substitution - coding silent
  229             c.686C\>T         p.S229L                 COSM417291           3       Substitution - missense

IL-34, interleukin-34.

###### 

Dataset content from the PrognoScan database demonstrating an association between microarray analyses in IL-34 and cancer prognosis.

  Database          Case type           Subsyte          No. of patients   Endpoint                Cutpoint   P-value   Prognosis   (Refs.)
  ----------------- ------------------- ---------------- ----------------- ----------------------- ---------- --------- ----------- --------------------------
  GSE12417-GPL570   Blood cancer        AML              79                Overall survival        0.18       0.028     1           ([@b45-ijmm-35-01-0092])
  GSE4412-GPL97     Brain cancer        Glioma           74                Overall survival        0.72       0.003     2           ([@b46-ijmm-35-01-0092])
  GSE17537          Colorectal cancer                    55                Overall survival        0.38       0.04      1           ([@b47-ijmm-35-01-0092])
  GSE31210          Lung cancer         Adenocarcinoma   204               Relapse-free survival   0.89       0.03      2           ([@b48-ijmm-35-01-0092])
  GSE8894           Lung cancer         NSCLC            138               Relapse-free survival   0.4        0.0002    1           ([@b49-ijmm-35-01-0092])

A total of 5 out of 40 tests showed an association between the expression of the IL-34 gene in microarray analysis and cancer prognosis (blood cancer, 1/4; brain cancer, 1/4; breast cancer, 0/11; colorectal cancer, 1/7; eye cancer, 0/1; head and neck cancer, 0/3; lung cancer, 2/6; ovarian cancer, 0/3; and skin cancer, 0/1) with a 5% significance level. IL-34, interleukin-34; NSCLC, non-small cell lung cancer.
